Assuntos
Diabetes Mellitus Tipo 2/tratamento farmacológico , Toxidermias/prevenção & controle , Hipersensibilidade Tardia/prevenção & controle , Hipoglicemiantes/efeitos adversos , Testes Imunológicos/métodos , Pirazinas/efeitos adversos , Pele/efeitos dos fármacos , Triazóis/efeitos adversos , Idoso , Diabetes Mellitus Tipo 2/complicações , Dipeptidil Peptidase 4/agonistas , Toxidermias/etiologia , Feminino , Humanos , Hipersensibilidade Tardia/etiologia , Hipoglicemiantes/imunologia , Hipoglicemiantes/uso terapêutico , Ativação Linfocitária , Masculino , Pessoa de Meia-Idade , Pirazinas/imunologia , Pirazinas/uso terapêutico , Fosfato de Sitagliptina , Pele/patologia , Triazóis/imunologia , Triazóis/uso terapêutico , Suspensão de TratamentoRESUMO
Incretin-based therapies are now well established for diabetes management and are among the frontline agents for control of hyperglycemia. In addition to their antihyperglycemic effects, evidence is emerging on the role of these agents on blood pressure regulation, cardioprotective and renoprotective properties. Because of the pleiotropic nature of these affects, these agents could offer significant benefits with regards to the cardiorenal metabolic complications that are part of the diabetes and obesity epidemic in the United States and worldwide. We review the various known mechanisms or pathways by which incretin based therapy exerts its regulation of blood pressure with emphasis on novel mechanisms such as inflammation/immunomodulation and oxidative stress.
Assuntos
Inibidores da Dipeptidil Peptidase IV/uso terapêutico , Hipertensão/tratamento farmacológico , Incretinas/uso terapêutico , Animais , Pressão Sanguínea/efeitos dos fármacos , Pressão Sanguínea/imunologia , Exenatida , Peptídeo 1 Semelhante ao Glucagon/agonistas , Humanos , Incretinas/imunologia , Estresse Oxidativo , Peptídeos/imunologia , Peptídeos/uso terapêutico , Pirazinas/imunologia , Pirazinas/uso terapêutico , Sistema Renina-Angiotensina/efeitos dos fármacos , Fosfato de Sitagliptina , Linfócitos T Reguladores/efeitos dos fármacos , Linfócitos T Reguladores/imunologia , Triazóis/imunologia , Triazóis/uso terapêutico , Peçonhas/imunologia , Peçonhas/uso terapêuticoAssuntos
Transplante de Medula Óssea/efeitos adversos , Transplante de Medula Óssea/métodos , Doença Enxerto-Hospedeiro/imunologia , Doença Enxerto-Hospedeiro/prevenção & controle , Imunossupressores/imunologia , Doença Aguda , Transplante de Medula Óssea/imunologia , Ácidos Borônicos/imunologia , Bortezomib , Doença Crônica , Ensaios Clínicos como Assunto , Cicloexanos/imunologia , Ciclofosfamida/imunologia , Ciclosporina/imunologia , Medicina Baseada em Evidências , Doença Enxerto-Hospedeiro/mortalidade , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Transplante de Células-Tronco Hematopoéticas/métodos , Humanos , Ácidos Hidroxâmicos/imunologia , Imunossupressores/administração & dosagem , Imunossupressores/farmacologia , Maraviroc , Metotrexato/imunologia , Pentostatina/imunologia , Transplante de Células-Tronco de Sangue Periférico/efeitos adversos , Transplante de Células-Tronco de Sangue Periférico/métodos , Pirazinas/imunologia , Qualidade de Vida , Tacrolimo/imunologia , Triazóis/imunologia , VorinostatRESUMO
Accumulating evidence supports the potential of proteasome inhibitors as immunosuppressants. Proteasome inhibitors interfere with antigen processing and presentation, as well as with the signaling cascades involved in immune cell function and survival. Both myeloma and healthy plasma cells appear to be highly susceptible to proteasome inhibitors due to impaired proteasomal activity in both cell types. As a consequence, these agents can be used to reduce antibody production and thus prevent antibody-induced tissue damage. Several clinical studies have explored the potential of bortezomib, a peptide boronate proteasome inhibitor, for treating immune disorders, such as antibody-mediated organ rejection and graft-versus-host disease (GVHD), with encouraging results. Here, we discuss the biological rationale for the use of proteasome inhibitors as immunosuppressive agents and review the clinical experience with bortezomib in immune-mediated diseases.
Assuntos
Rejeição de Enxerto/tratamento farmacológico , Doença Enxerto-Hospedeiro/tratamento farmacológico , Imunossupressores/imunologia , Imunossupressores/uso terapêutico , Complexo de Endopeptidases do Proteassoma/metabolismo , Inibidores de Proteassoma/imunologia , Inibidores de Proteassoma/uso terapêutico , Animais , Anticorpos/imunologia , Ácidos Borônicos/imunologia , Ácidos Borônicos/uso terapêutico , Bortezomib , Rejeição de Enxerto/enzimologia , Rejeição de Enxerto/imunologia , Doença Enxerto-Hospedeiro/enzimologia , Doença Enxerto-Hospedeiro/imunologia , Humanos , Pirazinas/imunologia , Pirazinas/uso terapêuticoRESUMO
OBJECTIVE: To report the usefulness of bortezomib therapy in a sensitized lung transplant recipient experiencing antibody-mediated rejection. CASE SUMMARY: During a pretransplant evaluation, a 62-year-old woman with usual interstitial pneumonitis developed a diverticular bleed requiring transfusions, which elevated her panel reactive antibody to 98% for human leukocyte antigen (HLA) class I and 71% for class II. She underwent desensitization to decrease her panel reactive antibody levels. She received a double lung transplant across a weak HLA class II incompatibility but developed respiratory failure due to early graft dysfunction. On postoperative day (POD) 14 she was found to have donor-specific antibodies (DSA) to HLA class I and class II antigens. She received intravenous immunoglobulin (IVIG), plasmapheresis, and bortezomib to reduce the DSA. Repeat DSA testing on POD 80 demonstrated a 50% reduction in DSA, which became undetectable at POD 255. DISCUSSION: Antibody-mediated rejection (AMR) is difficult to diagnose and treat in lung transplantation. Since primary treatment options such as plasmapheresis and IVIG alone may not adequately eradicate DSA, the proteasome inhibitor bortezomib can be of additional value for the treatment of AMR. Bortezomib causes apoptosis of plasma cells, thus eliminating the production of allograft-specific DSA. CONCLUSIONS: This is the first report describing the utility of bortezomib for early graft dysfunction in a highly sensitized lung transplant recipient. Although this patient had preformed donor-specific anti-HLA antibodies, AMR was successfully treated with a combination of plasmapheresis, IVIG, and bortezomib. At time of writing, the patient continued to have excellent graft function 2 years posttransplant. Bortezomib is a potent inhibitor of plasma cell production and it appears to be useful for the treatment of antibody-mediated graft dysfunction.
Assuntos
Ácidos Borônicos/uso terapêutico , Rejeição de Enxerto/prevenção & controle , Antígenos HLA/imunologia , Isoanticorpos/sangue , Transplante de Pulmão/imunologia , Inibidores de Proteases/uso terapêutico , Pirazinas/uso terapêutico , Ácidos Borônicos/administração & dosagem , Ácidos Borônicos/imunologia , Bortezomib , Feminino , Rejeição de Enxerto/imunologia , Humanos , Isoanticorpos/imunologia , Pessoa de Meia-Idade , Inibidores de Proteases/administração & dosagem , Inibidores de Proteases/imunologia , Pirazinas/administração & dosagem , Pirazinas/imunologia , Doadores de Tecidos , Resultado do TratamentoRESUMO
BACKGROUND: Current treatments for autoantibody-mediated diseases (i.e., systemic lupus erythematosus) and alloantibodies (in transplant) are minimally effective. Although they deplete naïve B cells, plasmablasts, and transiently reduce antibody concentrations, they are minimally effective against long-lived, antibody-producing plasma cells. In transplantation, plasma cells produce antibodies directed against human leukocyte antigen (HLA) antigens causing poor allograft survival. We report the first clinical experience with a plasma cell depleting therapy, bortezomib, to abrogate anti-HLA antibodies in transplantation (outside of rejection) in an attempt to improve long-term allograft survival. METHODS: Eleven patients with anti-HLA alloantibodies were treated with bortezomib. All patients underwent plasmapheresis to aid in removal of antibodies and to determine the effect of bortezomib. Serial measurements of anti-HLA antibody levels were conducted weekly by single antigen bead on Luminex platform. RESULTS: Bortezomib treatment elicited substantial reduction in both donor-specific antibody (DSA) and non-DSA levels. Antibodies were directed against DSA in 8 of 11 cases. Mean time to antibody appearance was 2 months posttransplant. Within 22 days (median) from treatment initiation, 9 of 11 patients' antibody levels dropped to less than 1000 mean fluorescence intensity. Of two patients without successful depletion, all had peak mean fluorescence intensity more than 10,000. At a mean follow-up of approximately 4 months posttreatment, all patients have stable graft function. Minimal transient side effects were noticed with bortezomib in the form of gastrointestinal toxicity, thrombocytopenia, and paresthesias. CONCLUSIONS: Bortezomib therapy effectively abrogates anti-HLA antibodies. Hence, removal of antibodies, by proteasome inhibition, represents a new treatment strategy for transplantation and may have benefit in autoimmune-related disease.
Assuntos
Rejeição de Enxerto/imunologia , Sobrevivência de Enxerto/imunologia , Antígenos HLA/imunologia , Isoanticorpos/sangue , Transplante de Rim/imunologia , Inibidores de Proteases/uso terapêutico , Inibidores de Proteassoma , Adulto , Ácidos Borônicos/imunologia , Ácidos Borônicos/uso terapêutico , Bortezomib , Antígenos HLA-D/imunologia , Antígenos de Histocompatibilidade Classe I/imunologia , Humanos , Isoanticorpos/imunologia , Doadores Vivos , Masculino , Inibidores de Proteases/imunologia , Complexo de Endopeptidases do Proteassoma/imunologia , Pirazinas/imunologia , Pirazinas/uso terapêutico , Transplante Homólogo/imunologia , Adulto JovemRESUMO
The ubiquitin-proteasome pathway is a well-characterized mechanism deputed to the degradation of intracellular proteins. Proteasomal degradation intervenes in the regulation of numerous cellular functions including signal transduction, apoptosis, cell cycle, and antigen presentation. In vitro and in vivo studies have shown that both normal and malignant cells of the immune system are exquisitely affected by inhibition of proteasome activity. This property is currently exploited in the treatment of multiple myeloma and mantle cell lymphoma, two B-cell malignancies that respond to treatment with the proteasome inhibitor bortezomib. Pharmacological inhibitors of the proteasome also affect function and survival of B and T lymphocytes and of dendritic cells and were shown to reduce autoimmune and inflammatory manifestations in several models of immune-mediated disorders. The present review offers an overview of the mechanisms implicated in the immunomodulatory effects of proteasome inhibitors and discusses prospective future applications for these small molecules in immune and inflammatory diseases.